Home
overview

SAE Media Group Introduces
Cell & Gene Therapy
19 - 20 June, 2023 | London, UK
-------------------------------------------------------------------------

SAE Media Group is proud to announce the inaugural Cell and Gene Therapy Conference taking place on the 19th – 20th June 2023.
As part of SAE Media Group’s leading series of drug discovery conferences, this year’s event will bring together expertise from individuals across the advanced therapeutics community. The two-day conference will offer a series of presentations, through which you will gain insight into the latest developments in discovery, development and delivery of cell and gene therapies.
 

 

Largely owing to the success and regulatory approvals of mRNA vaccines in recent years, there has been a renewed spotlight on cell and gene therapies and this “second-wave” is proving highly successful in accelerating R&D in the space through increased investment. This year’s conference will consider the latest approaches to therapeutic discovery and the impact of technologies such as AI and CRISPR/CAS-9. Novel approaches to delivery and screening have also taken hold and case studies on applications in oncology and rare diseases will demonstrate the enormous potential of cell and gene therapies for new and effective opportunities in personalised medicine.
 

This event will not only bring you the key insights you need to develop your cell and gene therapy pipeline by benchmarking against the latest case studies, but it will also give you the opportunity to network with key players throughout the industry.


We hope to welcome you to this must attend event in June 2023.
 

  •  EXPLORE the approaches being undertaken to develop cancer and rare disease treatments now to expand your future cell and gene therapy portfolio, with the potential for personalised cancer vaccines, stem-cell treatments for heart failure and haemophilia gene therapies
  • DISCOVER the latest industry developments in the cell and gene therapy field to expand your target range with updates and innovations in: direct CNS-delivery, off-the-shelf screening libraries and personalised neoantigen therapeutics
  • UNCOVER how CRISPR/cas9 has laid the foundation for the next-generation of gene-editing technologies and how challenges in safety, delivery and efficacy have been overcome with real-world-examples from AstraZeneca, CRISPR Therapeutics and Bayer
  • REVIEW approval case studies from a line-up of global industry experts from Astellas, Adaptimmune, Oxford Biomedica and the MHRA to better understand the regulatory pathways.
     

Academia Sinica; Adverum Biotechnology; Agency for Science; Allergan; Allergan Ltd; AstraZeneca; AstraZeneca PLC; Autolus Ltd; BenevolentAI; Caribou Biosciences, Inc.; Cell and Gene Therapy Catapult; Celyad; Chiesi Farmaceutici SpA; F.Hoffmann-La Roche; Fresenius Kabi Ltd; Innovate Uk; Inovio Pharmaceuticals Inc ; IQVIA; KU Leuven; LucidQuest; Medicines and Healthcare Products Regulatory Agency (MHRA); MeiraGTx; MHRA; NHSBT; NIBSC, MHRA; Novo Nordisk; Plasticell; Plasticell Ltd; Pluristem; Reneuron Group Plc; Roche; Selecta Biosciences Inc.; Takeda; Takeda Development Centre Europe Ltd.; UCl Clinical Trails Unit; University College London;

Conference programme

8:00 Registration & Coffee

9:00 Chairman's Opening Remarks

9:10 Applying different virus technologies to develop and manufacture a complete cell and gene therapy pipeline

Paulo Fernandes

Paulo Fernandes, Associate Director, Cell and Gene Therapy Technologies, Orchard Therapeutics
View Bio

  • Delving into the therapeutic benefits of hematopoietic stem cell gene therapies for genetic and other severe diseases
  • Structural and functional selected delivery systems considerations for gene therapies
  • Understanding the process of regulatory submission from preclinical development to manufacturing
  • Case study- OTL pipeline for neurometabolic disorders
  • 9:50 Addressing patient access challenges for advanced therapeutics

    Diego Ardigo

    Diego Ardigo, ATMP Project and Clinical Program Leader, Chiesi Farmaceutici SpA

  • Autologous versus allogeneic CAR-T cells vs gene therapies
  • Understanding safety and toxicology concerns for ATMPs from patient perspectives
  • Exploring the scalability of cell therapies and the move from R&D to clinic
  •  

    10:30 Morning Coffee

    11:00 A novel, disruptive gene therapy modality- Applicable to DNA

    Nagy Habib

    Nagy Habib, Co-Founder and CMO , Dawn Therapeutics

    11:40 Upgrading on traditional cell therapies with human iPS cell derived ventricular cardiomyocytes stem cell treatments for heart failure

    Takehiko Kaneko

    Takehiko Kaneko, CMO, HeartSeed

    12:20 Networking Lunch

    13:20 Evaluating the first wave of cell & gene therapies in Europe and the challenges and opportunities going forward

  • Improving the development time for cell and gene therapies with co-designed platforms 
  • Assessing the therapeutic potential and patient benefits for off-the-shelf cell therapies 
  • Evaluating the regulatory pathways for CGTs with considerations from other genomic medicines
  • Reviewing the growth in cell and gene therapy pipelines in a crowded market
  • Roberto Nitsch

    Roberto Nitsch, Director - Gene Therapy, Astrazeneca

    Pelin Candarlioglu

    Pelin Candarlioglu, Cell Biologist/Bioengineer - Complex in Vitro Models, GlaxoSmithKline

    Diego Ardigo

    Diego Ardigo, ATMP Project and Clinical Program Leader, Chiesi Farmaceutici SpA

    John Maher

    John Maher, Chief Scientific Officer, Leucid Bio

    14:00 Progressing the therapeutic potential of Mesenchymal-like Adherent Stromal Cells as effective cell therapies

    Lior  Raviv

    Lior Raviv, CTO, Pluristem

  • Applications for stromal cell derived regenerative medicines in mainstream medicine
  • Enhancement of viral transduction efficiency for autologous cell therapy to treat rare diseases
  • Applying Pluristem’s 3D manufacturing platform for cell therapies
  • 14:40 Afternoon Tea

    15:10 CAR T-cell immunotherapy of solid tumours – moving through the generations

    John Maher

    John Maher, Chief Scientific Officer, Leucid Bio

  • Summary of a dose escalation phase 1 clinical trial of panErbB CAR T-cells in patients with head and neck cancer
  • Summary of a novel CAR platform dubbed a lateral CAR
  • Demonstration of enhanced anti-tumour efficacy and functional persistence of lateral CAR T-cells compared to linear comparators
  • 15:50 Applications for the use of stem cells as therapeutic modalities

    Ningshu Liu

    Ningshu Liu, Head of Stem Cells, FosunPharma

  • Understanding the differences between stem cells therapy and cell therapy
  • Maximising therapeutic translation of stem cell research
  • Comparisons between ESCs, iPSCs and adult stem cells for autologous and allogenic therapies
  • Enriching regenerative strategies with stem-cell based therapies
     

     

  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    9:10 Taking a Recombinant Overlapping Approach

    William Finch

    William Finch, CEO, Oxford Vacmedix

  • Introduction into the recombinant overlapping peptide (ROP) platform
  • Outlining the wide applications of the ROP Technology platform such as cancer and infectious diseases
  • Discussion of advanced therapies in development
  • 9:50 Improving gene therapy efficacy and targeting for rare neuronal disorders

    10:30 Morning Coffee

    11:00 Applications of Improved Gene Therapy Methods in Neurologic Disorders

    Thomas Lowe

    Thomas Lowe, Clinical Development Scientist, AviadoBio

  • Assessing the use of gene therapies for both subcortical and cortical degeneration to rescue disease pathology
  • Promoting viral vector delivery through neuro-anatomy led approaches
  • Case studies from AviadoBio’s pre-clinical gene therapy pipeline
  •  

    11:40 The next level of CRISPR safety: tackling Cas9 immunogenicity.

    Roberto Nitsch

    Roberto Nitsch, Director - Gene Therapy, Astrazeneca

  • Highlighting how the safety of gene therapies depends on the accuracy of editing detection.
  • Profiling immunogenicity of currently approved gene edited therapies.
  • Case study from AstraZeneca’s CRISPR programme.
  • Optimising the development of animal models for gene-edited therapeutics
     
  • 12:20 Networking Lunch

    13:20 Studying neurodegenerative disorders with stem cell models

    Clare Jones

    Clare Jones, Chief Scientific Officer, Talisman Therapeutics

  • Opening the opportunity for CNS based gene therapies with human stem cell models
  • Accelerating drug target ID and validation with improved biologically relevant models
  • Case Studies of Talisman Therapeutics dementia and neurodegeneration

     

  • 14:00 Overcoming AAV gene therapy issues for with liver models of rare genetic diseases

    Giuseppe Ronzitti

    Giuseppe Ronzitti, Group Leader, Genethon

  • Understanding the liver as a model for rare genetic disorders
  • Overcoming concerns with humoral immunity and the toxicities associated to liver overloading in neuromuscular diseases 
  • Employing IdeS endopeptidase to degrade anti-AAV immunoglobulins
  • 14:40 Afternoon Tea

    15:10 Reviewing a novel gene therapy approach for chronic ocular diseases

    Andrew Osbourne

    Andrew Osbourne, Head of Biology, Ikarovec

  • Outlining the benefits of a multi-target approach
  • Exploring DMO and AMD as gene therapy targets 
  • Key Learnings from pre-clinical studies

     

  • 15:50 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Diego Ardigo

    Diego Ardigo

    ATMP Project and Clinical Program Leader, Chiesi Farmaceutici SpA
    John Maher

    John Maher

    Chief Scientific Officer, Leucid Bio
    Lior  Raviv

    Lior Raviv

    CTO, Pluristem
    Nagy Habib

    Nagy Habib

    Co-Founder and CMO , Dawn Therapeutics
    Paulo Fernandes

    Paulo Fernandes

    Associate Director, Cell and Gene Therapy Technologies, Orchard Therapeutics
    Roberto Nitsch

    Roberto Nitsch

    Director - Gene Therapy, Astrazeneca

    Adrien Lemoine

    Co-Founder and Chief Executive Officer, Bloomsbury Genetic Therapies
    Adrien Lemoine

    Andrew Osbourne

    Head of Biology, Ikarovec
    Andrew Osbourne

    Clare Jones

    Chief Scientific Officer, Talisman Therapeutics
    Clare Jones

    Diego Ardigo

    ATMP Project and Clinical Program Leader, Chiesi Farmaceutici SpA
    Diego Ardigo

    Giuseppe Ronzitti

    Group Leader, Genethon
    Giuseppe Ronzitti

    John Maher

    Chief Scientific Officer, Leucid Bio
    John Maher

    Lior Raviv

    CTO, Pluristem
    Lior  Raviv

    Nagy Habib

    Co-Founder and CMO , Dawn Therapeutics
    Nagy Habib

    Ningshu Liu

    Head of Stem Cells, FosunPharma
    Ningshu Liu

    Paulo Fernandes

    Associate Director, Cell and Gene Therapy Technologies, Orchard Therapeutics
    Paulo Fernandes

    Paulo is currently an Associate Director leading the Vector Process Development team at Orchard therapeutics, a cell and gene therapy company dedicated to transforming the lives of people affected by rare diseases. Paulo did his PhD at NOVA University of Lisbon/iBET in Portugal, later joining another cell and gene therapy company – Autolus Therapeutics – in the UK. Paulo’s career has been focused on cell line, analytical and bioprocess developments for viruses and viral vectors, and the respective transfer and manufacture to GMP. He is an active member of European Society for Animal Cell technology, and currently an executive committee member of this society;

    Pelin Candarlioglu

    Cell Biologist/Bioengineer - Complex in Vitro Models, GlaxoSmithKline
    Pelin Candarlioglu

    Roberto Nitsch

    Director - Gene Therapy, Astrazeneca
    Roberto Nitsch

    Takehiko Kaneko

    CMO, HeartSeed
    Takehiko Kaneko

    Thomas Lowe

    Clinical Development Scientist, AviadoBio
    Thomas Lowe

    William Finch

    CEO, Oxford Vacmedix
    William Finch

    William Finch

    CEO, Oxford Vacmedix
    William Finch

    Exhibitors

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Exhibitors


    Cherwell

    Exhibitors
    http://www.cherwell-labs.co.uk.

    Cherwell Laboratories Ltd is a UK manufacturer and supplier of the prepared media Redipor®. The Head Office is in Bicester, Oxfordshire and can boast an excellent transport network, which enables its abilities to work effectively with the Export and Distribution partners as well as all Domestic customers.

    With over 50 years’ experience, Cherwell has become a specialist supplier of ‘cleanroom microbiology solutions’ with products for environmental monitoring and process validation for healthcare, pharmaceutical and industrial applications.

    Because environmental monitoring is a critical element to any manufacturing process, Cherwell focuses on supplying high quality, reliable products, that are supported by expert knowledge. The range within the product portfolio enables professionals to make informed decisions about their cleanroom environment, and sterility processes. Which allows them to select the best suited solutions for them to manage risk associated with a robust contamination control strategy.

    The SAS air environmental sampling range is reliable and robust equipment known to conform to the Annex 1 requirement of 1m³.

    The new ImpactAIR is designed for high-risk graded environments, deploying a monitoring innovation that is called ‘slit to agar’. This system uses a Redipor 9cm plate rather than the standard 14cm. The process provides assurances on potential contamination within the cleanroom environment with a D50 value of 0.53 micron capturing the extremely small-scale particles, complying with the Annex 1 requirements

    We work in partnership within the market and take pride in sharing our knowledge, experience and expertise to ensure that everyone is using our portfolio in the best way possible for their environmental needs and expectations.


    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out